---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-26-000012"
form_type: "8-K/A"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:09:03.716809+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Aspira enters lab services pact with Mayo Clinic for Ova1Plus and OvaWatch tests

## Summary
- Agreement effective Dec 16, 2025; Mayo will list Aspira’s Ova1Plus and OvaWatch in its test catalog.
- Mayo obligated to set minimum list prices (redacted); will market tests to its clients.
- Initial term (redacted years) with automatic renewal; either party may terminate without cause on (redacted) days notice.
- Testing is non-exclusive and on an as-requested basis; many financial terms remain confidential.
- Partnership leverages Mayo’s national distribution to expand reach of Aspira’s ovarian cancer tests.

## SEC filing metadata
- accession: 0000926617-26-000012
- form_type: 8-K/A
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/0000926617-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/awhl-20251223x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-26-000012
- JSON: https://secwatch.observer/filing/0000926617-26-000012.json
- Plain text: https://secwatch.observer/filing/0000926617-26-000012.txt

## Key facts
- Material Agreements
  Aspira Women's Health Inc. entered into Laboratory Services Agreement with Mayo Collaborative Services, Inc. d/b/a Mayo Clinic Laboratories valued at Not disclosed (effective 2025-12-16).
  - Action: entry
  - Agreement: supply
  - Counterparty: Mayo Collaborative Services, Inc. d/b/a Mayo Clinic Laboratories
  - Value: Not disclosed
  - Effective: 2025-12-16
  source text: On December 23, 2025, Aspira Women’s Health Inc. (“Aspira”) disclosed that we had entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”), effective as of December 16, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/0000926617-26-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.